iShares Genomics Immunology and Healthcare ETF

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Moderna President Stephen Hoge Sells 53,336 Shares at $48.4 and Exercises Options

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Moderna Stock Surges 13% Amid Hantavirus Outbreak; Analysts Cite Limited Commercialization Potential

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Allworth Financial LP Increases Merck Holdings by 71.4%

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Arbutus Biopharma reports Q1 2026 net income of $169.7 million

Moderna Recognized for mRNA Achievements and Approved for Flu and COVID Combo Vaccine

Amundi Increases Stake in Merck Above 3% Threshold

Bayer Aktiengesellschaft released FY2026 Q1 earnings on May 12 Pre-Market EST, actual revenue USD 15.36 B (forecast USD 15.49 B), actual EPS USD 3.2202

Bernstein Analyst Reiterates Neutral Rating on Moderna

Merck Shows Latest Progress in Its Oncology Portfolio

Roche Launches New Blood Test for Alzheimer's Pathology with CE Certification

Moderna Presents mRNA-4359 Cancer Antigen Therapy Study Results

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ARKG

SBIO

IDNA

LABU

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek | CAI Stock News

StockTitan

Caris Life Sciences

iShares US Healthcare Providers

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares US Medical Devices

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek | CAI Stock News

IBBQ

Charles River Laboratories International Inc. (CRL) shares rose 1.67% to $152.43, breaking a four-day losing streak, despite a poor overall market day. The S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. CRL's stock remains 33.40% below its 52-week high of $228.88. Competitors had mixed results, with Labcorp down 0.74% and Alnylam Pharmaceuticals and Bio-Techne rising 2.81% and 2.34%, respectively.

MarketWatch Automated

Charles River Laboratorie

Invesco Nasdaq Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Labcorp

Alnylam Pharma

Bio-Techne

Factset Research

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

NTLA

J.P. Morgan analyst Brian Cheng has maintained a Sell rating on Intellia Therapeutics (NTLA) with a price target of $8.00, while the shares closed at $14.28. Cheng, a 4-star analyst, has an average return of 6.7% and a 52.55% success rate. Goldman Sachs also issued a Sell rating on Intellia, while Morgan Stanley maintained a Hold rating.

Tip Ranks

Intellia Therap

Franklin Genomic Adv ETF

Wisdomtree BioRevolution Fund ETF

JPMorgan Chase

Protagonist Therap

Revolution Medicines

Protara Therapeutic

Goldman Sachs

Morgan Stanley

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

MEDP

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

Medpace

SPDR S&P Health Equip

Direxion S&P Biotech Bear 3X

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

Charles River Laboratories (CRL) shares have declined 18% in the past month, closing at $149.93, despite a 1-year total return of 6.05%. Analysts suggest the stock may be undervalued, with a fair value estimate of $313.61, while a DCF model indicates a lower value of $78.12. Investors are encouraged to weigh these differing perspectives and consider other investment opportunities in the healthcare sector.

Simplywall

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

IDXX

Elyxium Wealth LLC has invested $3.67 billion in IDEXX Laboratories, acquiring 5,419,507 shares, which now represent 54.3% of its portfolio. Other institutional investors have also increased their stakes in IDEXX. The company's stock opened at $528.79, with a market cap of $41.71 billion and a P/E ratio of 38.94. IDEXX reported a quarterly EPS of $3.47, exceeding estimates, and has set FY 2026 guidance at 14.450-14.900 EPS.

Market Beat

IDEXX Labs

Bank of NY Mellon

Invesco

Principal Financial

Citigroup

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX

CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average analyst rating of "Moderate Buy" from eighteen analysts. The stock has two sell, five hold, ten buy, and one strong buy recommendations. The average 12-month price target is $66.06. Recent price targets include TD Cowen's hold rating at $45, Citigroup's buy rating at $82, and Piper Sandler's overweight rating at $110. The stock opened at $54.01, with a 52-week range of $34.87 to $78.48. The company reported a loss of $1.28 EPS for the last quarter and had revenue of $1.46 million.

CRISPR Therap

Toronto Dominion Bank

Piper Sandler Cos

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts

Wells Fargo analyst Brandon Couillard has maintained a Buy rating on Guardant Health (GH) with a price target of $125.00. Couillard, a 5-star analyst, has an average return of 15.6% and a success rate of 58.51%. Guardant Health also received a Buy rating from Guggenheim’s Subbu Nambi, while Evercore ISI maintained a Hold rating on May 8.

Guardant Health

Wells Fargo

Bio-Rad Lab

Myriad Genetic

Evercore

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Bio-Rad Lab-B

Guardant Health (GH) Gets a Buy from Wells Fargo

Guardant Health, Inc. announced the approval of restricted stock units (RSUs) for 267 new non-executive employees, totaling 143,898 shares, under the 2023 Employment Inducement Incentive Award Plan. The RSUs, granted as inducements for employment, will vest annually over three years. This action complies with Nasdaq Listing Rule 5635(c)(4).

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

World Investment Advisors acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) by purchasing 16,290 shares valued at approximately $1.66 million in Q4. Other investors, including AQR Capital Management and Sei Investments, also increased their holdings. Guardant Health's stock opened at $94.92, with a market cap of $12.59 billion. The company reported a quarterly revenue of $281.27 million, up 39.4% year-over-year, but missed EPS estimates. Analysts have mixed ratings, with a consensus price target of $129.42.

SEI Investments

Manulife Financial

Raymond James Financial

Barclays

UBS Group AG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH

iShares Genomics Immunology and Healthcare ETF(IDNA.US)

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek | CAI Stock News

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts

Guardant Health (GH) Gets a Buy from Wells Fargo

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH